GlassScriptPhysician profile
Haven R Malish
NPI 1831283936
$16,145.29
in general payments reported to CMS, 2019-2025
32 companies · $3,953 in 2025
The $3,953 reported for 2025 was more than what 86% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $943 · 2020: $725 · 2021: $630 · 2022: $2,803 · 2023: $720 · 2024: $6,371 · 2025: $3,953.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $5,500 · Food and Beverage: $3,012 · Travel and Lodging: $2,532.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $5,500.00 |
| Food and Beverage | $3,011.51 |
| Travel and Lodging | $2,532.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $7,196.68 | 2019-2025 | Inspire |
| Intuitive Surgical, INC. | $6,971.14 | 2023-2025 | Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals LP | $228.37 | 2019-2024 | Airsupra, Tezspire |
| Melinta Therapeutics, LLC | $226.01 | 2019-2025 | Rezzayo, Orbactiv, Kimyrsa |
| Harmony Biosciences LLC | $218.29 | 2020-2025 | Wakix |
| Glaxosmithkline, LLC. | $168.30 | 2020-2024 | Nucala |
| Mallinckrodt Hospital Products INC. | $136.29 | 2020-2024 | Acthar |
| Grifols USA, LLC | $125.27 | 2019-2024 | Prolastin-C Liquid |
| Merck Sharp & Dohme LLC | $123.24 | 2019-2025 | Zerbaxa, Dificid, Prevymis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.13 | 2021-2023 | Ofev |
| Insmed, INC. | $99.65 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $83.58 | 2019-2024 | Opsumit, Uptravi |
| Abiomed | $61.22 | 2023 | Impella |
| Baxter Healthcare | $47.31 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Philips North America LLC | $38.33 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $36.43 | 2021-2024 | Glassia |
| Aimmune Therapeutics, INC. | $33.96 | 2024 | |
| Shire North American Group INC | $23.34 | 2019 | |
| Ucb, INC. | $20.79 | 2019 | |
| Pharmacosmos Therapeutics INC. | $17.79 | 2024 | Monoferric |
| Janssen Biotech, INC. | $17.28 | 2024 | Stelara |
| Intercept Pharmaceuticals, INC. | $16.63 | 2024 | |
| Alexion Pharmaceuticals, INC. | $15.89 | 2022 | |
| Amgen INC. | $15.75 | 2019 | |
| Ardelyx, INC. | $14.72 | 2024 | Ibsrela |
| Mylan Specialty L.P. | $14.49 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.73 | 2019 | |
| Jazz Pharmaceuticals INC. | $12.19 | 2020 | |
| Sanofi-Aventis U.S. LLC | $12.00 | 2021 | |
| Fisher & Paykel Healthcare INC | $11.75 | 2021 | |
| Allergan, INC. | $11.74 | 2019 | |
| Genentech USA, INC. | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haven Malish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.